OncoMatch/Clinical Trials/NCT04205552
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
Is NCT04205552 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab 10 MG/ML Intravenous Solution and Relatlimab 10 MG/ML Intravenous Solution for nsclc stage ii.
Treatment: Nivolumab 10 MG/ML Intravenous Solution · Relatlimab 10 MG/ML Intravenous Solution — The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage I B, II, SELECTED STAGE III A
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: LAG-3 inhibitor
Prior treatment with Lymphocyte-activation gene 3 (LAG-3) targeting Agent
Cannot have received: anti-PD-1 therapy (nivolumab)
Previous treatment with Nivolumab
Cannot have received: other immune checkpoint inhibitor (relatlimab)
Previous treatment with Relatlimab
Cannot have received: preoperative antineoplastic treatment including irradiation
Any other concurrent preoperative antineoplastic treatment including irradiation
Lab requirements
Blood counts
Adequate hematological function parameters
Kidney function
Adequate renal function parameters
Liver function
Adequate hepatic function parameters
Cardiac function
Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
Adequate hematological, hepatic and renal function parameters; Sufficient cardiac left ventricular defined as left ventricular ejection fraction (LVEF) ≥ 50% documented either by echocardiography or multigated acquisition scan (MUGA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify